IDT expanded manufacturing capacity at its Coralville, Iowa facility to increase oligonucleotide synthesis output more than threefold. The expansion includes installation of additional synthesizers and high-throughput equipment and aligns with IDT’s NGS innovation roadmap and its move toward in vitro diagnostics, including a first IVD NGS assay announced earlier this year. In bioprocessing, Sartorius launched the CellCelector CLD automated imaging and cell isolation platform aimed at accelerating monoclonal cell line development. The workflow targets faster identification and isolation of top clones, with claims of compressing timelines and improving clone outgrowth versus standard approaches. Separately, FDA and CMS announced a new Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway for breakthrough-designated devices, designed to reduce time between authorization and Medicare national coverage decisions. While not limited to manufacturing, the pathway directly affects market-access timing and downstream production planning for device makers.